109 related articles for article (PubMed ID: 12053447)
1. [Retrospective study on the incidence and cause of drop-out during intracavernous pharmaco-prosthesis therapy].
Giammusso B; Motta M
Arch Ital Urol Androl; 2002 Mar; 74(1):27-31. PubMed ID: 12053447
[TBL] [Abstract][Full Text] [Related]
2. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates.
Polito M; d'Anzeo G; Conti A; Muzzonigro G
BJU Int; 2012 Dec; 110(11 Pt C):E954-7. PubMed ID: 23078100
[TBL] [Abstract][Full Text] [Related]
3. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
Kunelius P; Lukkarinen O
Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
[TBL] [Abstract][Full Text] [Related]
4. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
Engel JD; McVary KT
Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
[TBL] [Abstract][Full Text] [Related]
5. Intracavernous Alprostadil Alfadex--an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study.
Porst H; Buvat J; Meuleman E; Michal V; Wagner G
Int J Impot Res; 1998 Dec; 10(4):225-31. PubMed ID: 9884918
[TBL] [Abstract][Full Text] [Related]
6. [Intracavernous injections of prostaglandin E1 in the treatment of erection disorders].
Beretta G; Zanollo A; Portalupi W
Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):481-5. PubMed ID: 1838836
[TBL] [Abstract][Full Text] [Related]
7. Reasons for patient drop-out from an intracavernous auto-injection programme for erectile dysfunction.
Armstrong DK; Convery AG; Dinsmore WW
Br J Urol; 1994 Jul; 74(1):99-101. PubMed ID: 8044533
[TBL] [Abstract][Full Text] [Related]
8. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction.
El-Sakka AI
Int J Impot Res; 2006; 18(2):180-5. PubMed ID: 16163370
[TBL] [Abstract][Full Text] [Related]
9. [Erection disorders: efficacy and tolerability after 6 months of intracavernous self-injections of alprostadil. Groupe Français d'Etude de l'Alprostadil].
Giuliano F; Blanchet P; Banzet O; Lancrenon S; Benoît G; Jardin A
Presse Med; 1994 Oct; 23(33):1516-21. PubMed ID: 7824478
[TBL] [Abstract][Full Text] [Related]
10. Intracavernosal therapy for erectile failure--impact of treatment and reasons for drop-out and dissatisfaction.
Purvis K; Egdetveit I; Christiansen E
Int J Impot Res; 1999 Oct; 11(5):287-99. PubMed ID: 10553808
[TBL] [Abstract][Full Text] [Related]
11. Office treatment: intracavernous injections of prostaglandin E1 (PG E1) and improvement of spontaneous erections.
Beretta G; Marzotto M; Zanollo A; Re B
Acta Eur Fertil; 1991; 22(4):221-3. PubMed ID: 1844326
[TBL] [Abstract][Full Text] [Related]
12. Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment.
Alexandre B; Lemaire A; Desvaux P; Amar E
J Sex Med; 2007 Mar; 4(2):426-31. PubMed ID: 17367438
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
[TBL] [Abstract][Full Text] [Related]
14. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
Vardi Y; Lidgi S; Moskovitz B; Levin RD
Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
[TBL] [Abstract][Full Text] [Related]
15. [Intracavernous auto-injection of prostaglandin E1 for diagnosis and treatment of erectile dysfunction].
Arielly J; Weinberg D; Eliraz A; Adam M; el-Hanani BI; Eisenkraft S
Harefuah; 1994 Apr; 126(7):369-73, 426. PubMed ID: 8200581
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of sexual impotency by intra-cavernous injections of prostaglandin E1. Report of 180 patients].
Amar E; Kobelinsky M; Khoury R; Sarkis P; Bouyer I; Dauphin A; Delmas V; Boccon-Gibod L
Prog Urol; 1993 Dec; 3(6):971-8. PubMed ID: 8305940
[TBL] [Abstract][Full Text] [Related]
18. Reasons for high drop-out rate with self-injection therapy for impotence.
Weiss JN; Badlani GH; Ravalli R; Brettschneider N
Int J Impot Res; 1994 Sep; 6(3):171-4. PubMed ID: 7735362
[TBL] [Abstract][Full Text] [Related]
19. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
[TBL] [Abstract][Full Text] [Related]
20. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
Sung HH; Ahn JS; Kim JJ; Choo SH; Han DH; Lee SW
Andrology; 2014 Jan; 2(1):45-50. PubMed ID: 24194017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
